It Looks Like The CEO Of Innovent Biologics, Inc. (HKG:1801) May Be Underpaid Compared To Peers

Key Insights

• Innovent Biologics will host its Annual General Meeting on 25th of June
• Total pay for CEO Michael Yu includes CN¥2.90m salary
• The total compensation is 57% less than the average for the industry
• Over the past three years, Innovent Biologics' EPS grew by 54% and over the past three years, the total shareholder return was 158%

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

The impressive results at Innovent Biologics, Inc. (HKG:1801) recently will be great news for shareholders. This would be kept in mind at the upcoming AGM on 25th of June which will be a chance for them to hear the board review the financial results, discuss future company strategy and vote on resolutions such as executive remuneration and other matters. Let's take a look at why we think the CEO has done a good job and we'll present the case for a bump in pay.

See our latest analysis for Innovent Biologics

How Does Total Compensation For Michael Yu Compare With Other Companies In The Industry?

According to our data, Innovent Biologics, Inc. has a market capitalization of HK$130b, and paid its CEO total annual compensation worth CN¥41m over the year to December 2024. Notably, that's an increase of 11% over the year before. While we always look at total compensation first, our analysis shows that the salary component is less, at CN¥2.9m.

On comparing similar companies in the Hong Kong Biotechs industry with market capitalizations above HK$63b, we found that the median total CEO compensation was CN¥94m. In other words, Innovent Biologics pays its CEO lower than the industry median. Moreover, Michael Yu also holds HK$8.4b worth of Innovent Biologics stock directly under their own name, which reveals to us that they have a significant personal stake in the company.

On an industry level, roughly 52% of total compensation represents salary and 48% is other remuneration. Innovent Biologics pays a modest slice of remuneration through salary, as compared to the broader industry. If non-salary compensation dominates total pay, it's an indicator that the executive's salary is tied to company performance.

Innovent Biologics, Inc.'s Growth

Over the past three years, Innovent Biologics, Inc. has seen its earnings per share (EPS) grow by 54% per year. It achieved revenue growth of 52% over the last year.

Overall this is a positive result for shareholders, showing that the company has improved in recent years. Most shareholders would be pleased to see strong revenue growth combined with EPS growth. This combo suggests a fast growing business. Historical performance can sometimes be a good indicator on what's coming up next but if you want to peer into the company's future you might be interested in this free visualization of analyst forecasts.

Has Innovent Biologics, Inc. Been A Good Investment?

We think that the total shareholder return of 158%, over three years, would leave most Innovent Biologics, Inc. shareholders smiling. As a result, some may believe the CEO should be paid more than is normal for companies of similar size.

To Conclude...

Given the improved performance, shareholders may be more forgiving of CEO compensation in the upcoming AGM. However, despite the strong growth in earnings and share price growth, the focus for shareholders would be how the company plans to steer the company towards sustainable profitability in the near future.

CEO compensation is a crucial aspect to keep your eyes on but investors also need to keep their eyes open for other issues related to business performance. That's why we did some digging and identified 1 warning sign for Innovent Biologics that you should be aware of before investing.

Arguably, business quality is much more important than CEO compensation levels. So check out this free list of interesting companies that have HIGH return on equity and low debt.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.